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Effective treatments for irritable bowel syndrome with constipation
(IBS-C) are lacking.
Aim
To assess the efficacy and safety of lubiprostone in IBS-C.
Methods
A combined analysis was performed among 1171 patients with a Rome
II diagnosis of IBS-C in two phase-3 randomized trials of lubiprostone
8 mcg vs. placebo twice daily for 12 weeks. Using a balanced seven-
point Likert scale ranging from significantly relieved (+3), to signifi-
cantly worse ()3), patients responded on their electronic diary to the
question: ‘How would you rate your relief of IBS symptoms over the
past week compared to how you felt before you entered the study?’. The
primary efficacy endpoint was the percentage of overall responders.
Results
Using an intent-to-treat analysis with last observation carried forward,
a significantly higher percentage of lubiprostone-treated patients were
considered overall responders compared with those treated with placebo
(17.9% vs. 10.1%, P = 0.001). Patients treated with lubiprostone
reported a similar incidence of adverse events to those treated with
placebo.
Conclusions
The percentage of overall responders based on patient-rated assessments
of IBS-C symptoms was significantly improved in patients treated with
lubiprostone 8 mcg twice daily compared to those treated with placebo.
Lubiprostone was well tolerated with a favourable safety profile.
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INTRODUCTION
The irritable bowel syndrome (IBS) is defined by the
presence of abdominal discomfort or pain in associa-
tion with altered bowel habits (i.e. constipation, diar-
rhoea or a mixture of both).1 Of the approximately 30
million individuals in North America who meet the
diagnostic criteria for IBS, approximately one-third
experience constipation during episodes of disease
activity.2 The remaining patients experience diarrhoea
or mixed episodes between constipation and diar-
rhoea.2, 3 Several underlying mechanisms have been
implicated in the pathophysiology of IBS, although
much remains poorly understood.4, 5 As a conse-
quence, most currently available therapies are aimed
at alleviating specific symptoms.
Lubiprostone is an orally active prostone that
stimulates chloride secretion through activation of
type-2 chloride channels (ClC-2) in the gastrointesti-
nal tract. Through this action, lubiprostone enhances
gastrointestinal fluid secretion and transit and
improves the symptoms of constipation.6, 7 Recent
animal studies also suggest a role for this drug in
stabilizing mucosal membranes, which may help
reduce mucosal inflammation and membrane sensiti-
zation.8, 9 Lubiprostone was approved in the US for
the treatment of adults with chronic idiopathic con-
stipation (CC) in 2006 and for the treatment of IBS
with constipation (IBS-C) in adult females in 2008.10
In a post hoc analysis of patients from a pivotal
phase-3 trial of patients with CC who indicated IBS
as a confounding condition, treatment with lubipro-
stone was associated with significant improvement
in bowel movement frequency as well as symptoms
of abdominal discomfort ⁄ pain and bloating as com-
pared to placebo.11 A subsequent phase-2b dose
ranging study also identified benefits of lubiprostone
for IBS-C.7
Based on the encouraging results of the post hoc
analysis from the pivotal CC trials and phase-2b IBS-C
trial, two phase-3 trials were designed to evaluate the
efficacy and safety of lubiprostone 8 mcg administered
twice daily in patients with IBS-C.
AIMS
The objectives of this analysis were to demonstrate the
efficacy and safety of 12-week administration of oral
lubiprostone when compared to placebo for the treat-
ment of IBS-C. Lubiprostone was evaluated at a daily




Two phase-3 double-blind, randomized, placebo-
controlled trials (protocol numbers SIB-0431 and SIB-
0432) were conducted at multiple centres across the
US. The protocols and all study procedures were
approved by the Institutional Review Board at each
centre and the studies were conducted in accordance
with the World Medical Association Declaration of
Helsinki, the International Conference on Harmonisa-
tion Tripartite Guideline for Good Clinical Practice and
applicable federal and local regulations. Prior to per-
formance of any study-related procedure, all patients
enrolled in the studies received comprehensible infor-
mation about the trial in which they would be partici-
pating and each signed an informed consent
document.
Both clinical trials were registered at http://clinical
trials.gov and received registration IDs NCT00380250,
NCT00399542. Results are posted at http://clinical
trials.gov under the same registration IDs. These trials
have not been published in full elsewhere.
The inclusion criteria for the two studies were the
same, with eligible patients being at least 18 years of
age and meeting the Rome II Modular Questionnaire
Criteria for Constipation-Predominant IBS.12 Patients
50 years or older were required to have had a colonos-
copy performed within the previous 5 years and after
the onset of IBS symptoms to rule out other possible
diseases. Patients under the age of 50 years were
required to have a sigmoidoscopy performed. Patients
excluded from study participation were those who
were unable or unwilling to use an acceptable method
of birth control; females who were pregnant or nurs-
ing and those with a potential for noncompliance with
the study protocol. Additional exclusion criteria
included those with: previous gastrointestinal or
abdominal surgery (except for common causes unre-
lated to IBS); organic disorder of the large or small
bowel (e.g. ulcerative colitis, Crohn’s disease); mechan-
ical obstruction; unexplained significant weight loss or
rectal bleeding; diagnosis of any medical condition
associated with constipation (other than IBS); or con-
ditions that might interfere with the conduct of the
study, including other significant medical conditions,
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renal impairment, cancer, abnormal laboratory tests,
recent abuse of alcohol or drugs, use of any medica-
tion indicated for treatment of IBS within the 4 weeks
preceding randomization or use of investigational
medications during the 4 weeks prior to screening.
Study protocols
The study designs are presented in Figure 1. For the
purposes of this manuscript, the ‘optional extension
study’ referred to in both schema will not be presented,
nor will ‘Treatment Period Phase II’ of study 0431.
Patients meeting the inclusion criteria entered a 4-
week baseline ⁄ screening period that preceded each of
the two studies. Those who did not have a flexible sig-
moidoscopy or colonoscopy within the previous
5 years underwent the relevant endoscopic procedure
during this period. During the 4-week screening per-
iod, patients were required to discontinue all laxative
medications [over-the-counter (OTC) and prescription]
and other specified disallowed medications for the
duration of the study and were instructed to maintain
a stable diet with no significant changes in their con-
sumption of liquids or fibre or in their level of physi-
cal activity. During the screening period, patients
accessed an electronic diary system on a daily basis to
report the occurrence and time of all spontaneous
bowel movements (SBMs), defined as those that
occurred without the use of rescue medications.
Patients used symptom scales previously utilized11 that
included BM consistency (rated as 0 = very loose,
1 = loose, 2 = normal, 3 = hard and 4 = very hard),
constipation severity, straining, abdominal bloating
and discomfort (rated as 0 = absent, 1 = mild,
2 = moderate, 3 = severe and 4 = very severe). If the
patient did not experience a BM for 3 or more consec-
utive days and needed relief, the study investigator
could authorize the patient to administer a rescue
medication. Initial rescue treatment consisted of a
10 mg Dulcolax (bisacodyl; Boehringer Ingelheim
GmbH, Ingelheim Rhein, Germany). If this was not
successful a Fleet enema (dibasic sodium phosphate
and monobasic sodium phosphate; C.B. Fleet, Lynch-
burg, VA, USA) could then be used. If both of these
treatment options were unsuccessful, an alternative
medication could be prescribed after consultation with
the investigator.
At the end of the screening period, patients were
assessed by medical history, physical examination, and
laboratory tests. They completed an IBS quality of life
questionnaire (IBS-QOL) as well.13 Daily diary data
were reviewed and those who met the inclusion crite-
ria, with >70% completion of their electronic daily
diary with these data indicating abdominal discom-
fort ⁄ pain with a monthly average assessment of mild
or greater severity and any two of the following symp-
toms: <3 SBMs per week at least 25% of the time, at
least 25% of SBMs recorded a straining assessment of
moderate or greater severity, at least 25% of SBMs
recorded a stool consistency assessment of hard or
very hard stool, were eligible to enter the double-blind
phases of their respective trial.
Patients enrolled in each trial were randomized to
receive either lubiprostone 8 mcg or placebo capsules
using a computer-generated randomization scheme.
Each drug was administered twice daily with breakfast
and dinner with at least 8 ounces of water for a period
of 12 weeks. A reduction to once-daily dosing was
allowed, at the discretion of the investigator, if the
patient experienced nausea or diarrhoea for more than
2 days or if patients experienced other adverse events.
During treatment, patients were prohibited from taking
prescription or OTC medications for constipation. Use
of a daily fibre supplement was permitted, but patients
were recommended to keep stable fibre therapy
throughout the study period. Nonconstipation-related
prescriptions and other OTC medications were allowed
and their usage was documented as was as any medi-
cation change. As in the screening period, the use of
rescue medications was allowed in those who failed to
have a BM for 3 or more consecutive days and thus
needed relief.
During the 12-week study phase, clinic visits were
conducted at weeks 4, 8, and 12 and phone interviews
were performed at weeks 1 and 2 following the final
study visit. Patients continued to access the electronic
diary system to report their SBMs, BM consistency and
symptoms of constipation, medication usage and con-
stipation rescue medications. On a weekly basis,
patients also answered the electronic diary question:
‘How would you rate your relief of IBS symptoms over
the past week compared with how you felt before you
entered the study?’ using a seven-point balanced scale.
At each clinic visit, the daily diary information was
reviewed and discussed with the patient, adverse
events were recorded, remaining capsules were col-
lected to assess compliance and assessments of vital
signs and laboratory parameters were performed.
Patients also completed the IBS-QOL at week 4 and 12
visits.
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Figure 1. (a) Schematic of Study 0431. (b) Schematic of Study 0432. Note: For each study, the ‘Optional Extension Study’
methodology and results are not presented in this article. For study 0431, Treatment period Phase II methodology and
results are not presented in this article.
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Efficacy endpoints
The primary efficacy endpoint of the studies and the
combined analysis was the overall responder status in
the lubiprostone and placebo groups. This endpoint was
calculated from the weekly assessments of symptom
relief gathered as part of the patient’s electronic diary
responses to the question ‘How would you rate your
relief of IBS symptoms over the past week compared to
how you felt before you entered the study?’ There were
seven possible response options on a balanced scale that
included ‘Significantly worse’, ‘Moderately worse’, ‘A
little bit worse’, ‘Unchanged’, ‘A little bit relieved’,
‘Moderately relieved’ or ‘Significantly relieved’ (Fig-
ure 2). A weekly responder was defined as reporting
either moderately or significantly relieved for that week.
Monthly responders were defined as those who rated
their IBS symptoms as being at least moderately relieved
for all 4 weeks of the month or significantly relieved for
at least 2 weeks of the month, with no ratings of moder-
ately or severely worse. In addition, the patient could
not discontinue treatment during the 4-week period due
to a lack of efficacy, and the percent of days of rescue
medication use did not increase compared to baseline. A
patient was considered an overall responder (primary
efficacy endpoint) if they were monthly responders for
at least 2 of the 3 months of the study.
Secondary efficacy endpoints included the patient’s
monthly responder status, the weekly responder rate
and the symptom rating changes from baseline for
their abdominal discomfort ⁄ pain, bloating, BM and
SBM frequency, stool consistency, degree of straining,
constipation severity and symptom relief as rated on
five-point Likert scales ranging from 0 (absent) to 4
(very severe). The assessment of stool consistency was
scored on a scale of 0 (very loose) to 4 (very hard).
Each patient’s subjective evaluation of the efficacy of
treatment was recorded weekly using a scale of 0 (not
at all effective) to 4 (extremely effective). Rescue med-
ication use was also recorded. The effects of treatment
on health-related QOL were evaluated using a vali-
dated questionnaire for assessing IBS-QOL.13
Safety and tolerability
Safety endpoints included recording of all adverse
events, clinical laboratory analyses at multiple time-
points, vital signs and physical examinations.
Statistical analyses
Each study was statistically powered in identical fash-
ion. Within each study, 570 subjects were required in
a 2:1 randomization (lubiprostone:placebo). This sam-
ple size within each study provided at least 88% statis-
tical power to observe a relative 70.6% increase in
overall responders for lubiprostone compared to pla-
cebo. All primary and secondary efficacy endpoint
analyses reported were performed on an intent-to-treat







5-A little bit relieved
3-A little bit worse
4-Unchanged
“How would you rate your relief of lBS symptoms (abdominal discomfort/pain, bowel
habits, and other lBS symptoms) over the past week compared to how you felt
before you entered the study?”  
Monthly Responder:  A response of “moderately relieved” or better in 4 out of 4 weeks
~ or ~
A response of “significantly releved” in 2 out of 4 weeks 
Overall Responder:  A monthly responder for at least 2 out of the 3 months of the trial
Figure 2. Rigorous responder definition.
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study drug and had data available for at least one effi-
cacy endpoint. To accommodate potential variability
in baseline values, we performed analyses using
changes from baseline rather than raw values. Baseline
values were defined as the average of all daily values
during the 4-week screening ⁄ baseline period. Analyses
of adverse events and other safety parameters included
all patients who received at least one dose of study
drug.
The study designs of 0431 and 0432 were similar in
design and conducted in parallel; therefore, we present
the studies’ results as a combined analysis. The com-
bined analysis also provides greater power for signal
identification in safety and efficacy endpoints. The
analyses of the combined data were stratified by study.
A Cochran–Mantel–Haenszel test stratified by study
was used to analyse overall and monthly responder
rates. To test significance at a given month (months
1–3 only) while protecting the experiment-wise type I
error rate of a = 0.05, a combination of closed and
sequential testing procedures were performed. The pro-
cedure involved three steps. The method of analysis of
each step is described as follows: For step 1, the num-
ber of responder months during the first 2 months was
summed for each subject so that each subject received
a score of 0, 1 or 2. If the CMS test resulted in a P-
value <0.05, then the procedure advanced into step 2.
Otherwise, the procedure stopped. In step 2, months 1
and 2 were tested individually and simultaneously.
Statistical significance was declared for any test that
results in a P-value <0.05. If statistical significance
was declared for both months 1 and 2, then the testing
procedure advanced into step 3. Otherwise, the proce-
dure stopped. In step 3, month 3 was tested individu-
ally. This stepwise procedure was applied individually
to the studies and combined and both analyses are
presented here.
The treatment effect from an analysis of covariance
(ANCOVA) was used to test for differences between the
treatment groups for all secondary symptom end-
points. The ANCOVA model controlled for study and the
baseline value was used as a covariate. The ANCOVA
model was used to examine the relationship between
change in symptoms and response.
The IBS-QOL responses were scored according to the
user’s manual and scaled scores were used for all analy-
ses.13 ANCOVA were used to analyse IBS-QOL responses.
All efficacy analyses with the exception of IBS-QOL
used the last observation carried forward (LOCF) pro-
cedure to impute data for missing observations.
RESULTS
The subject disposition of both studies is presented in
Figure 3. In total, 1171 patients in both studies were
randomized to receive either lubiprostone or placebo
after completing the 4-week screening ⁄ baseline period
and satisfying the inclusion criteria. In both studies,
four patients withdrew before receiving study medica-
tion and therefore were not included in either safety
or efficacy analyses. A total of 13 patients withdrew
after receiving study drug but before undergoing any
postdosing evaluations. These patients were included
in the safety, but not in the efficacy analysis. Thus,
1154 patients were included in the efficacy (ITT) anal-
ysis and 1167 were included in the safety analysis.
In both studies, patients were mostly female
(91.6%), Caucasian (77.4%) and had a mean age of
46.6 years. At baseline, mean total abdominal scores
for abdominal discomfort ⁄ pain (2.08; moderate),
abdominal bloating (2.26; moderate), constipation
severity (2.23; moderate), weekly SBM frequency
(3.88), stool consistency (2.76; normal-hard) and
straining (2.39; moderate) were similar between the
lubiprostone and placebo groups. Only the category of
age showed a statistically significant (P < 0.05) differ-
ence between lubiprostone and placebo groups, which
was not deemed clinically meaningful. Baseline demo-
graphics and disease-specific characteristics are pre-
sented in Table 1. There were no significant
differences in baseline symptom scores between the
two combined studies, thus permitting the combined
analysis of data.
Primary endpoint
In a combined (ITT with LOCF) analysis, the total num-
ber of overall responders in the lubiprostone group
(17.9%) was significantly higher than that in the pla-
cebo group (10.1%; P = 0.001). These results are
depicted in Figure 4).
Individually, both studies showed a statistically sig-
nificantly higher number of overall responders and
significance at the first month as well as at other
months with respect to responders who received lubi-
prostone treatment (Table 2).
The symptoms of abdominal discomfort ⁄ pain, bloat-
ing, constipation severity, stool consistency and strain-
ing correlated with responder status (Figure 5),
indicating the validity of the seven-point balanced
scale. On average, responders had a greater than one
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point reduction in their assessment of the IBS-C symp-
toms, whereas nonresponders showed only a one-third
point reduction in their ratings. This also correlates
with a clinically meaningful change (one point on a
five-point scale, or a shift towards normal stools)14 in
the responder group.
Secondary endpoints
The combined percentage of monthly responders
using LOCF (Figure 6) was also significantly higher
among those treated with lubiprostone compared
with those treated with placebo at month 2 (18.3%
vs. 11.4%, P = 0.003) and at month 3 (22.0% vs.
14.5%, P = 0.003). There was a trend towards a
significantly higher percentage of monthly respond-
ers with lubiprostone compared with placebo at
month 1 (10.8% vs. 7.5%, P = 0.078). For weekly
responder rates, significant improvements were seen
in the combined analysis with lubiprostone vs.
placebo at weeks 2, 4, 5, 6, 10 and 12 (P £ 0.030;
Figure 7).
Mean improvement from baseline in abdominal dis-
comfort ⁄ pain was significantly greater in lubiprostone-
treated patients compared with placebo-treated patients
at month 2 ()0.43 vs. )0.35, P = 0.039) and month 3
ITT - 193 ITT - 390
(1 patient not treated)
ITT - 192
(2 patients no postdose data)
Completion rate - 73.9%
Discontinuation Discontinuation
n = 56/194 (28.4%) n = 99/396 (25.0%)
Adverse event - 4.6% Adverse event - 5.1%
Lack of efficacy - 4.1% Lack of efficacy - 2.5%
Lost to follow-up - 2.1% Lost to follow-up - 2.0%
Withdrew consent - 14.4% Withdrew consent - 9.8%
Noncompliance - 1.5% Noncompliance - 3.3%
Other - 1.5%
ITT - Intent-to-Treat Population
Other - 2.3%
Discontinuation
n = 84/387 (21.7%)
Adverse event - 4.7%
Lack of efficacy - 4.7%
Lost to follow-up - 1.6%




n = 43/194 (22.2%)
Adverse event - 7.7%
Lack of efficacy - 4.1%
Lost to follow-up - 3.1%
Withdrew consent - 5.2%
Noncompliance - 1.5%
Other - 0.5%
Completion rate - 78.1%
(1 patient not treated)
(5 patients no postdose data)
ITT - 379
(2 patients not treated)
(6 patients no postdose data)
Placebo
n = 194 n = 194
PlaceboLubiprostone
n = 396 n = 396
Lubiprostone
Study 0431




Figure 3. Patient disposition.
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()0.45 vs. )0.36, P = 0.028). Mean improvement from
baseline in the lubiprostone group was significantly
greater than the mean observed with placebo for
abdominal bloating at month 2 (P = 0.044); BM fre-
quency at month 1 (P = 0.021); stool consistency at
months 1, 2 and 3 (P £ 0.022); and degree of straining
at months 1 and 2 (P £ 0.013) (Table 3).
Quality of life
In the overall analysis of IBS-QOL, there was a trend
towards greater improvement with lubiprostone at
week 12 (P = 0.066). Analysis of subdomains demon-
strated that ‘body image’ and ‘health worry’ were sig-
nificantly improved in the lubiprostone group at week
Table 1. Combined demographic and baseline characteristics of patients receiving at least one dose of study medication
and having at least one postbaseline efficacy measurement
Parameter
Treatment group
Total (n = 1154) P-valuePlacebo (n = 385) Lubiprostone (n = 769)
Age (years)
n 385 769 1154 0.049*
Mean (min, max) 47.7 (18.0, 85.0) 46.1 (19.0, 83.0) 46.6 (18.0, 85.0)
s.d. 12.94 12.84 12.89
Gender
Female 359 (93.2%) 698 (90.8%) 1057 (91.6%) 0.152
Male 26 (6.8%) 71 (9.2%) 97 (8.4%)
Race
American Indian ⁄ Alaska Native 0 (0.0%) 1 (0.1%) 1 (0.1%) 0.053
Asian 2 (0.5%) 3 (0.4%) 5 (0.4%)
Black ⁄ African American 50 (13.0%) 102 (13.3%) 152 (13.2%)
Caucasian 298 (77.4%) 595 (77.4%) 893 (77.4%)
Hispanic ⁄ Latino 30 (7.8%) 68 (8.8%) 98 (8.5%)
Other 5 (1.3%) 0 (0.0%) 5 (0.4%)
Abdominal discomfort ⁄ pain
n 385 769 1154 0.814
Mean (min, max) 2.08 (0.46, 4.00) 2.07 (0.36, 4.00) 2.08 (0.36, 4.00)
s.d. 0.667 0.658 0.661
Abdominal bloating
n 385 769 1154 0.961
Mean (min, max) 2.26 (0.57, 4.00) 2.26 (0.62, 4.00) 2.26 (0.57, 4.00)
s.d. 0.694 0.684 0.687
Constipation severity
n 385 769 1154 0.485
Mean (min, max) 2.25 (0.32, 4.00) 2.22 (0.00, 3.96) 2.23 (0.00, 4.00)
s.d. 0.645 0.661 0.655
Weekly SBM frequency
n 385 769 1154 0.752
Mean (min, max) 3.84 (0.00, 28.81) 2.22 (0.00, 36.5) 3.88 (0.00, 36.5)
s.d. 3.571 3.320 3.405
SBM stool consistency
n 364 745 1109 0.834
Mean (min, max) 2.75 (0.57, 4.00) 2.76 (0.00, 4.00) 2.76 (0.00, 4.00)
s.d. 0.690 0.658 0.668
SBM bowel straining
n 364 745 1109 0.774
Mean (min, max) 2.40 (0.00, 4.00) 2.39 (0.00, 4.00) 2.39 (0.00, 4.00)
s.d. 0.742 0.699 0.713
SBM, spontaneous bowel movement.
* Statistically significant (P £ 0.05).
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12 (P £ 0.025). With a third domain, dysphoria, there
was a trend for improvement in lubiprostone-treated
patients, but this was not statistically significant
(P = 0.086). Lubiprostone produced clinically mean-
ingful changes (>14 points)13 in the IBS-QOL domains
of social reaction, food avoidance, health worry, body
image and dysphoria.
Safety and adverse events
Overall, 588 (50%) patients reported at least one
adverse event (Table 4). There was a similar incidence
of adverse events in both treatment groups: 50% of
lubiprostone and 51% of placebo-treated patients
reported at least one adverse event. Most adverse
events were mild-to-moderate in intensity and
resolved without intervention. The most frequently
reported adverse events were related to the gastroin-
testinal tract (i.e. nausea, diarrhoea and abdominal dis-
tension) and occurred with similar incidence in both
treatment groups (lubiprostone = 19%, placebo =
14%). Patients who withdrew because of an adverse
event are detailed in Figure 3. There were no signifi-
cant differences between patients who withdrew from
the lubiprostone groups and those in the placebo
group.
A total of 11 serious adverse events (defined
as those that were fatal, life-threatening, required
hospitalization or intensive medical intervention) were
reported during the trials, seven (1%) in the lubipro-
stone group and four (1%) in the placebo group. One
serious adverse event was considered possibly related
to lubiprostone, an episode of noncardiac chest pain in
a 69-year-old female with a pre-existing cardiac medi-
cal history who was hospitalized one day after initiat-
ing treatment with lubiprostone. A cardiac workup
ruled out cardiac cause, and the patient’s chest pain
resolved the next day. One patient randomized to the
lubiprostone treatment arm died during the study. The
patient, a 71-year-old male with a history of diabetes
mellitus, hyperlipoidaemia and obesity, experienced a
fatal cardiac arrest after 72 days of lubiprostone treat-
ment. The investigator did not consider the patient’s
death as related to administration of lubiprostone
given the patient’s longstanding medical history.
No clinically significant differences between the two
patient groups were detected in the analyses of labora-
tory values, vital signs or physical examination.
DISCUSSION
In the past, therapeutic modalities for IBS-C included
bulking agents, osmotic laxatives and tegaserod, a par-




















ITT with LOCF Population
Monthly responder for ≥ 2/3 months during treatment
Figure 4. Combined overall responder rate.
Table 2. Overall and monthly responder rates by individual study (intent-to-treat, last observation carried forward
population)
Treatment group (Study 0431)
P-value*
Treatment group (Study 0432)
P-value*
Placebo (n = 193) (%) Lubiprostone (n = 390) (%) Placebo
(n = 192) (%)
Lubiprostone
(n = 379) (%)
Timepoint
Overall 9.8 18.2 0.009 10.4 17.7 0.031
Month 1 7.8 11.0 0.174 7.3 10.6 0.278
Month 2 10.9 18.7 0.016 12.0 17.9 0.074
Month 3 14.5 21.3 0.053 14.6 22.7 0.026
* P-values are from Cochran–Mantel–Haenszel tests stratified by centre.
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benefit to some patients, but are generally not more
effective than placebo at relieving global IBS symp-
toms and may increase important IBS abdominal
symptoms such as bloating. There exists very limited
clinical trial evidence that supports the efficacy of
osmotic laxatives in relieving abdominal discomfort or
pain.15, 16 Tegaserod has demonstrated clinical efficacy
in ameliorating different IBS-related symptoms, but
has recently been withdrawn in many countries
because of concerns regarding cardiovascular safety
issues.17 In the US, tegaserod is now only available
through an emergency treatment investigational new
drug application for patients with clinical circum-
stances, which are ‘immediately life-threatening or
serious enough to qualify for hospitalization’.18
The two trials described here contributed to FDA’s
approval in May 2008 of lubiprostone for the
treatment of IBS-C in adult women.10 The results of
Baseline score








*0 (absent), 1 (mild), 2 (moderate), 3 (severe), 4 (very severe)
†0 (very loose [watery]), 1 (loose), 2 (normal), 3 (hard), 4 (very hard [little balls])






















Figure 5. Lubiprostone symp-
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Combined ITT with LOCF population
4/4 weeks with ≥ “moderately relieved” OR
≥ 2/4 weeks with “significantly relieved”
Not meeting any restriction criteria

























Figure 7. Combined weekly responder rate. P < 0.05.
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the combined data from these two phase-3 trials pro-
vide support for the efficacy of lubiprostone at a dosage
of 8 mcg twice daily in treating the global and individ-
ual symptoms experienced by patients with IBS-C.
Lubiprostone significantly improved the chances of an
IBS-C patient to become a responder (vs. a nonre-
sponder) compared to placebo. Importantly, patients in
the lubiprostone group had statistically significantly
more (approximately twofold) treatment responders
than those in the placebo group. These significant dif-
ferences also occurred for the monthly responder rate
at months 2 and 3 in both trials. Patients treated with
lubiprostone experienced significant improvement in
all secondary endpoints: abdominal discomfort ⁄ pain,
bloating, straining and severity of constipation, as well
as increased BM frequency and stool consistency. For
most of these symptoms, the effect of lubiprostone per-
sisted for the 3-month duration of the studies.
The relatively low response rates reported in the
lubiprostone and placebo groups for the primary end-
point deserve discussion. These studies utilized a
novel, highly rigorous responder definition, which was
developed in conjunction with the US Food and Drug
Administration. To be considered a monthly responder,
patients had to report moderate relief of their IBS
symptoms for 4 of 4 weeks or significant relief for
more than 2 of 4 weeks. To be an overall responder,
patients had to be a monthly responder for 2 of
3 months of the randomization period. It is possible
that this highly rigorous endpoint may have underesti-
mated the proportion of patients whom a practicing
clinician would have considered successfully treated.
For example, patients who reported moderate relief of
their IBS symptoms for 3 of 4 weeks were not consid-
ered a monthly responder using this endpoint. Simi-
larly, those with moderate relief of their IBS symptoms
for 2 weeks and significant relief for 1 week were not
considered a monthly responder. Furthermore, these
studies’ responder definition included not only patient
self-assessment but also disallowed increased rescue
medication use and study discontinuation because of
lack of treatment efficacy. The rigour of the primary
endpoint is highlighted by the placebo response of
10%, a value lower than has been reported in previ-
ous IBS treatment trials.19 Despite the rigour of the
primary endpoint, patients randomized to lubiprostone
were nearly twice as likely to experience an overall
improvement in IBS symptoms compared to those
receiving placebo.
These current studies further demonstrate the bene-
fit of lubiprostone in treating the constipation-associ-
ated symptoms of IBS. It is likely that these clinical
benefits are mediated through the activation of ClC-2
channels20, 21 leading to increased fluid secretion into
the intestinal lumen. Furthermore, the activation by
lubiprostone of ClC-2 channels has been shown in
animal studies to initiate restoration of tight junc-
tions, leading to recovery of mucosal barrier func-
tion.9, 22 Recent studies suggest that increased
intestinal permeability may be a contributing factor
to the IBS clinical state.23 Thus, it is attractive to
speculate that reduced intestinal permeability associ-
ated with an increased inflammatory response23–26
may enable the development of visceral hyper-
sensitivity that is often present in patients with IBS.











Treatment-related adverse events 21 22
Nausea 4 8
Diarrhoea 4 6
Abdominal distension 2 2
Study discontinuation
because of adverse event
7 5
* Includes all patients who received at least one dose of
study medication.
 One patient reported a noncardiac related chest pain that
was deemed possibly because of lubiprostone.
Table 3. Combined secondary efficacy endpoint summary
(intent-to-treat, last observation carried forward popula-
tion)
Symptom measure Month 1 Month 2 Month 3
Abdominal discomfort ⁄ pain * *
Abdominal bloating *
Bowel movement Frequency *
Straining * * *
Constipation severity * * *
Stool consistency * * *
* Statistically significant (P £ 0.05).
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Possibly, lubiprostone may inhibit this effect in IBS
which in turn may explain the improved global
symptoms and pain scores. This finding may have
important clinical implications for IBS-C as other an-
ticonstipation agents like polyethylene glycol do not
show pain benefit.27
Overall, lubiprostone at a dose of 8 mcg twice
daily was well-tolerated. There were no significant
differences between the lubiprostone and placebo
groups in reporting adverse events or serious adverse
events. The most frequently-reported AEs were gas-
trointestinal-related and included nausea (8% with
lubiprostone and 4% with placebo), diarrhoea (6%
with lubiprostone and 4% with placebo) and abdom-
inal distension (2% in both groups). With respect to
the nausea, most events were mild or moderate in
nature, were much less frequent compared with
higher dosages used for treating chronic constipation
and resolved without intervention. The higher rate of
diarrhoea in the lubiprostone group is consistent
with the drug’s mechanism of action.21 The reason
for the higher incidence of nausea among IBS-C
patients receiving lubiprostone is unknown, but con-
sistent with results seen in previous chronic consti-
pation studies.7, 11 The only serious adverse event
that was considered possibly related to treatment,
noncardiac chest pain in a patient with a pre-exist-
ing cardiac medical history, resolved within 24 h. In
previous clinical trials of constipated adults receiving
24 mcg lubiprostone twice daily, no treatment-
related cardiac deaths or serious adverse events have
been reported.7, 11
Based on results from a previous phase-2 trial,7
lubiprostone significantly improved gastrointestinal
symptoms of IBS-C across three dosing groups (8,
16 and 24 mcg twice daily each) and the benefit in
terms of pain was similar across all doses. The study
determined that the 8 mcg twice daily dose of lubi-
prostone demonstrated the optimal combination of
efficacy and safety for IBS-C. The results of this
combined analysis of two phase-3 trials confirm the
findings of the earlier phase-2 trial, with significant
improvement in IBS-C symptoms reported for most
parameters and a demonstrated an acceptable safety
profile. For reasons of the unique primary endpoint
response definition, the results are not comparable
across IBS trials using a different primary endpoint
definition.
In these 2 trials, lubiprostone treatment was associ-
ated with a trend towards improvement in overall
QOL. Furthermore, statistically significant improve-
ments were seen in key subdomains (body image,
health worry) with lubiprostone as compared to
placebo. The overall trend was not seen in the
previous phase-2 study, where no treatment differ-
ences were seen. The significant health worry
improvement with lubiprostone was also seen in the
previous trial.
CONCLUSION
The combined analysis of these two phase-3 trials
demonstrated that treatment with lubiprostone led to
a significantly higher number of global responders
and significantly improved individual symptoms in
patients with IBS-C compared with placebo. The clin-
ical benefits of lubiprostone were generally sustained
over 12 weeks of the treatment period. Treatment
with lubiprostone was associated with a similar over-
all incidence of adverse events as placebo; most of
the events were gastrointestinal in nature, mild-to-
moderate in intensity and short-lived. The frequency
of serious adverse events and patient withdrawals
from the study because of adverse events was similar
with lubiprostone and placebo. From these data, we
conclude that lubiprostone at a dose of 8 mcg admin-
istered twice daily provides an efficacious and well
tolerated treatment option for patients with IBS-C.
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